title: Acne treatment and inflammatory bowel disease: what is the evidence?
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota. Electronic address: alikhan.mirza@mayo.edu.
authors.forename: Ali
authors.initials: A
authors.lastname: Alikhan
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Henderson
authors.affiliation: West Virginia University School of Medicine, Morgantown, West Virginia.
authors.forename: Lauren
authors.initials: L
authors.lastname: Becker
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Gabriel F
authors.initials: GF
authors.lastname: Sciallis
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000139:chemically induced*; D015474:Isotretinoin / Q000009:adverse effects* / Q000627:therapeutic use; D013752:Tetracycline / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D015474:Isotretinoin; D013752:Tetracycline